Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets
Molecular markers of clinical outcome may aid in designing targeted treatments for bladder cancer. However, only a few bladder cancer biomarkers have been examined as therapeutic targets. Data from The Cancer Genome Atlas (TCGA) and bladder specimens were evaluated to determine the biomarker potenti...
Saved in:
Published in | British journal of cancer Vol. 117; no. 10; pp. 1507 - 1517 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Nature Publishing Group
07.11.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Molecular markers of clinical outcome may aid in designing targeted treatments for bladder cancer. However, only a few bladder cancer biomarkers have been examined as therapeutic targets.
Data from The Cancer Genome Atlas (TCGA) and bladder specimens were evaluated to determine the biomarker potential of the hyaluronic acid (HA) family of molecules - HA synthases, HA receptors and hyaluronidase. The therapeutic efficacy of 4-methylumbelliferone (4MU), a HA synthesis inhibitor, was evaluated in vitro and in xenograft models.
In clinical specimens and TCGA data sets, HA synthases and hyaluronidase-1 levels significantly predicted metastasis and poor survival. 4-Methylumbelliferone inhibited proliferation and motility/invasion and induced apoptosis in bladder cancer cells. Oral administration of 4MU both prevented and inhibited tumour growth, without dose-related toxicity. Effects of 4MU were mediated through the inhibition of CD44/RHAMM and phosphatidylinositol 3-kinase/AKT axis, and of epithelial-mesenchymal transition determinants. These were attenuated by HA, suggesting that 4MU targets oncogenic HA signalling. In tumour specimens and the TCGA data set, HA family expression correlated positively with β-catenin, Twist and Snail expression, but negatively with E-cadherin expression.
This study demonstrates that the HA family can be exploited for developing a biomarker-driven, targeted treatment for bladder cancer, and 4MU, a non-toxic oral HA synthesis inhibitor, is one such candidate. |
---|---|
AbstractList | Molecular markers of clinical outcome may aid in designing targeted treatments for bladder cancer. However, only a few bladder cancer biomarkers have been examined as therapeutic targets.
Data from The Cancer Genome Atlas (TCGA) and bladder specimens were evaluated to determine the biomarker potential of the hyaluronic acid (HA) family of molecules - HA synthases, HA receptors and hyaluronidase. The therapeutic efficacy of 4-methylumbelliferone (4MU), a HA synthesis inhibitor, was evaluated in vitro and in xenograft models.
In clinical specimens and TCGA data sets, HA synthases and hyaluronidase-1 levels significantly predicted metastasis and poor survival. 4-Methylumbelliferone inhibited proliferation and motility/invasion and induced apoptosis in bladder cancer cells. Oral administration of 4MU both prevented and inhibited tumour growth, without dose-related toxicity. Effects of 4MU were mediated through the inhibition of CD44/RHAMM and phosphatidylinositol 3-kinase/AKT axis, and of epithelial-mesenchymal transition determinants. These were attenuated by HA, suggesting that 4MU targets oncogenic HA signalling. In tumour specimens and the TCGA data set, HA family expression correlated positively with β-catenin, Twist and Snail expression, but negatively with E-cadherin expression.
This study demonstrates that the HA family can be exploited for developing a biomarker-driven, targeted treatment for bladder cancer, and 4MU, a non-toxic oral HA synthesis inhibitor, is one such candidate. Background:Molecular markers of clinical outcome may aid in designing targeted treatments for bladder cancer. However, only a few bladder cancer biomarkers have been examined as therapeutic targets.Methods:Data from The Cancer Genome Atlas (TCGA) and bladder specimens were evaluated to determine the biomarker potential of the hyaluronic acid (HA) family of molecules - HA synthases, HA receptors and hyaluronidase. The therapeutic efficacy of 4-methylumbelliferone (4MU), a HA synthesis inhibitor, was evaluated in vitro and in xenograft models.Results:In clinical specimens and TCGA data sets, HA synthases and hyaluronidase-1 levels significantly predicted metastasis and poor survival. 4-Methylumbelliferone inhibited proliferation and motility/invasion and induced apoptosis in bladder cancer cells. Oral administration of 4MU both prevented and inhibited tumour growth, without dose-related toxicity. Effects of 4MU were mediated through the inhibition of CD44/RHAMM and phosphatidylinositol 3-kinase/AKT axis, and of epithelial-mesenchymal transition determinants. These were attenuated by HA, suggesting that 4MU targets oncogenic HA signalling. In tumour specimens and the TCGA data set, HA family expression correlated positively with β-catenin, Twist and Snail expression, but negatively with E-cadherin expression.Conclusions:This study demonstrates that the HA family can be exploited for developing a biomarker-driven, targeted treatment for bladder cancer, and 4MU, a non-toxic oral HA synthesis inhibitor, is one such candidate. |
Author | Lokeshwar, Vinata B Morera, Daley S Soloway, Mark S Manoharan, Murugesan Terris, Martha K Kramer, Mario W Hennig, Martin S Garcia-Roig, Michael Lopez, Luis E Kallifatidis, Georgios Jordan, Andre R Merseburger, Axel S Lokeshwar, Soum D Wang, Jiaojiao Ortiz, Nicolas Talukder, Asif Yates, Travis J |
Author_xml | – sequence: 1 givenname: Daley S surname: Morera fullname: Morera, Daley S organization: Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Boulevard, Room CN 1177A, Augusta, GA 30912-2100, USA – sequence: 2 givenname: Martin S surname: Hennig fullname: Hennig, Martin S organization: Department of Urology, University Hospital Schleswig-Holstein, Kiel, Lübeck 23538, Germany – sequence: 3 givenname: Asif surname: Talukder fullname: Talukder, Asif organization: Department of Surgery, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA – sequence: 4 givenname: Soum D surname: Lokeshwar fullname: Lokeshwar, Soum D organization: Honors Program in Medical Education, University of Miami-Miller School of Medicine, 1600 NW 10th Avenue, Miami, FL 33136, USA – sequence: 5 givenname: Jiaojiao surname: Wang fullname: Wang, Jiaojiao organization: Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Boulevard, Room CN 1177A, Augusta, GA 30912-2100, USA – sequence: 6 givenname: Michael surname: Garcia-Roig fullname: Garcia-Roig, Michael organization: Department of Urology, University of Miami-Miller School of Medicine, 1600 NW 10th Avenue, Miami, FL 33136, USA – sequence: 7 givenname: Nicolas surname: Ortiz fullname: Ortiz, Nicolas organization: Department of Urology, University of Miami-Miller School of Medicine, 1600 NW 10th Avenue, Miami, FL 33136, USA – sequence: 8 givenname: Travis J surname: Yates fullname: Yates, Travis J organization: Sheila and David Fuente Graduate Program in Cancer Biology, Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, 1600 NW 10th Avenue, Miami, FL 33136, USA – sequence: 9 givenname: Luis E surname: Lopez fullname: Lopez, Luis E organization: Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Boulevard, Room CN 1177A, Augusta, GA 30912-2100, USA – sequence: 10 givenname: Georgios surname: Kallifatidis fullname: Kallifatidis, Georgios organization: Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA – sequence: 11 givenname: Mario W surname: Kramer fullname: Kramer, Mario W organization: Department of Urology, University Hospital Schleswig-Holstein, Kiel, Lübeck 23538, Germany – sequence: 12 givenname: Andre R surname: Jordan fullname: Jordan, Andre R organization: Sheila and David Fuente Graduate Program in Cancer Biology, Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, 1600 NW 10th Avenue, Miami, FL 33136, USA – sequence: 13 givenname: Axel S surname: Merseburger fullname: Merseburger, Axel S organization: Department of Urology, University Hospital Schleswig-Holstein, Kiel, Lübeck 23538, Germany – sequence: 14 givenname: Murugesan surname: Manoharan fullname: Manoharan, Murugesan organization: Miami Cancer Institute, Baptist Health South Florida, 8900 N Kendall, Miami, FL 33176, USA – sequence: 15 givenname: Mark S surname: Soloway fullname: Soloway, Mark S organization: Memorial Healthcare System, 20801 Biscayne Blvd Ste 203, Aventura, FL 33180, USA – sequence: 16 givenname: Martha K surname: Terris fullname: Terris, Martha K organization: Department of Surgery, Division of Urology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA – sequence: 17 givenname: Vinata B surname: Lokeshwar fullname: Lokeshwar, Vinata B organization: Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Boulevard, Room CN 1177A, Augusta, GA 30912-2100, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28972965$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkc1LJDEQxYO46Ojubc9LYK_2bJKe7iQeFkT8WBD2oudQ-Roz25O0Sbcw_70ZdEVPRfFevXrwO0GHMUWH0HdKlpS04pfemCUjlC9bKg7QgnYta6hg_BAtCCG8IZKRY3RSyqaukgh-hI6ZkJzJvlsguN3BMOcUg8FggsUetmHY4RCxHsBal7GBaFw-x2OaXJwCDHjMaR1TmeqNDmkL-Z_LBUO0eHp0GUY376UJ8tpN5Sv64mEo7tvbPEUP11f3l7fN3d-bP5cXd41ZcTE1XrfaWMKdkF3LpfYOOqENaGgJXXFpdFV0B713zHnCuQXKgTGvre68Ze0p-v2aO85666ypXTMMasyhFtypBEF9VmJ4VOv0rLpekFXf14CfbwE5Pc2uTGqT5hxrZ0VlT1dEUr53nb26TE6lZOffP1Ci9kBUBaL2QFQFUu0_PrZ6N_8n0L4AKTyMiA |
CitedBy_id | crossref_primary_10_1038_s41389_020_0233_0 crossref_primary_10_1016_j_biopha_2019_109433 crossref_primary_10_3390_biologics3040022 crossref_primary_10_1039_D2RA04984H crossref_primary_10_3389_fonc_2022_982231 crossref_primary_10_1016_j_tranon_2020_100900 crossref_primary_10_1016_j_trecan_2020_06_005 crossref_primary_10_1002_adbi_202300168 crossref_primary_10_1155_2020_6034670 crossref_primary_10_1016_j_canlet_2018_07_036 crossref_primary_10_1002_ar_24321 crossref_primary_10_3389_fimmu_2020_00073 crossref_primary_10_3390_cancers16061195 crossref_primary_10_3390_jfb11040072 crossref_primary_10_1186_s12935_022_02818_1 crossref_primary_10_1002_biof_1957 crossref_primary_10_1016_j_isci_2024_109191 crossref_primary_10_1111_coa_13390 crossref_primary_10_1038_s41598_019_40436_6 crossref_primary_10_1016_j_matbio_2018_04_012 crossref_primary_10_1038_s41420_021_00672_0 crossref_primary_10_3390_biom10111525 crossref_primary_10_1111_bph_14808 crossref_primary_10_1016_j_matbio_2018_01_021 crossref_primary_10_1152_ajpcell_00019_2022 crossref_primary_10_1080_10408347_2024_2373923 crossref_primary_10_1111_febs_14847 crossref_primary_10_3390_cancers16101907 crossref_primary_10_3390_chemosensors11070367 crossref_primary_10_3390_polym14163410 crossref_primary_10_1021_acsami_3c09564 crossref_primary_10_1002_iub_2608 crossref_primary_10_1016_j_semcancer_2019_07_007 crossref_primary_10_1002_ddr_21835 crossref_primary_10_1016_j_carbpol_2017_12_047 crossref_primary_10_1038_s41420_019_0176_4 crossref_primary_10_1096_fba_2022_00006 crossref_primary_10_3390_cancers13020260 crossref_primary_10_3390_cancers13071650 crossref_primary_10_1007_s12672_022_00543_9 crossref_primary_10_1155_2021_5524486 crossref_primary_10_3390_ijms21175983 crossref_primary_10_1016_j_mattod_2021_03_012 crossref_primary_10_1158_1078_0432_CCR_19_2912 crossref_primary_10_1038_s41416_022_01999_w crossref_primary_10_1093_glycob_cwaa046 crossref_primary_10_18632_aging_202982 crossref_primary_10_1007_s00432_019_03024_9 |
Cites_doi | 10.1016/j.yexcr.2009.03.002 10.1158/0008-5472.CAN-15-3114 10.1074/jbc.M008432200 10.1016/j.clgc.2016.07.021 10.1016/j.matbio.2016.10.001 10.1002/cncr.10652 10.1155/2016/8205836 10.1186/s12885-016-2570-0 10.1158/0008-5472.CAN-07-2140 10.1007/s13277-013-1604-3 10.3892/ol.2013.1124 10.1016/S0022-5347(05)66296-9 10.1002/cncr.25565 10.1016/j.juro.2009.06.070 10.18632/oncotarget.10529 10.3389/fimmu.2015.00182 10.1038/bjc.2011.459 10.1111/cei.12815 10.1158/0008-5472.CAN-09-3185 10.1158/1078-0432.CCR-15-1706 10.1093/glycob/cwr158 10.1002/ijc.20368 10.1016/S1078-1439(03)00032-2 10.1002/ijc.29975 10.1002/cncr.27661 10.1158/0008-5472.CAN-04-2805 10.1080/19336918.2015.1016686 10.1016/j.eururo.2015.10.024 10.1097/MPA.0000000000000741 10.1002/ijc.30460 10.1046/j.1432-1033.2002.03217.x 10.1016/S0022-5347(05)68050-0 10.1016/j.urolonc.2015.04.014 10.1016/j.canlet.2016.02.031 10.1074/jbc.M405918200 10.1016/B978-0-12-800092-2.00001-0 10.1016/j.bcp.2013.04.022 10.1002/ijc.22222 10.1016/j.eururo.2009.03.057 10.1158/0008-5472.CAN-06-1121 10.1002/cncr.26520 10.1158/0008-5472.CAN-05-1022 10.1159/000369357 10.1093/jnci/djv085 |
ContentType | Journal Article |
Copyright | Copyright Nature Publishing Group Nov 7, 2017 Copyright © 2017 Cancer Research UK 2017 Cancer Research UK |
Copyright_xml | – notice: Copyright Nature Publishing Group Nov 7, 2017 – notice: Copyright © 2017 Cancer Research UK 2017 Cancer Research UK |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AN0 AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ PQEST PQQKQ PQUKI PRINS 5PM |
DOI | 10.1038/bjc.2017.318 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database (ProQuest) Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts PHMC-Proquest健康医学期刊库 ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central British Nursing Database ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | MEDLINE ProQuest Central Student |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Targeting of HA family biomarkers |
EISSN | 1532-1827 |
EndPage | 1517 |
ExternalDocumentID | 10_1038_bjc_2017_318 28972965 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA176691 – fundername: NCI NIH HHS grantid: R01 CA227277 – fundername: NCI NIH HHS grantid: R01 CA072821 – fundername: NCI NIH HHS grantid: R21 CA184018 – fundername: NCI NIH HHS grantid: F31 CA210612 |
GroupedDBID | --- -Q- 0R~ 23N 36B 39C 3V. 4.4 406 53G 5GY 5RE 6J9 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AANZL AASML AATNV AAWBL AAWTL AAZLF ABAKF ABLJU ABOCM ABUWG ABZZP ACAOD ACBMV ACBRV ACBYP ACGFO ACGFS ACIGE ACKTT ACPRK ACRQY ACTTH ACVWB ACZOJ ADBBV ADFRT ADHDB ADMDM ADYYL AEFQL AEFTE AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFKRA AFNRJ AFRAH AFSHS AGAYW AGEZK AGGBP AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJCLW AJDOV AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF AN0 AOIJS ASPBG AVWKF AXYYD AZFZN BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BNQBC BPHCQ BVXVI CCPQU CGR CS3 CUY CVF DIK DNIVK DPUIP DU5 E3Z EAP EBLON EBS ECM EE. EIF EIOEI EJD ESX EX3 F5P FDQFY FEDTE FERAY FIGPU FIZPM FRJ FSGXE FYUFA GX1 HCIFZ HMCUK HVGLF HYE HZ~ IH2 IWAJR JSO JZLTJ KQ8 M1P M7P NAO NAPCQ NPM NQJWS O9- OK1 P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT RPM SNX SNYQT SOHCF SRMVM SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D WH7 WOW XFK ZA5 ~02 AACDK AAYXX CITATION 7TO 7U9 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ H94 K9. LK8 PQEST PQUKI PRINS 5PM |
ID | FETCH-LOGICAL-c478t-fb3bcd07e895379bfea58bcaba301479cbe89b5a6fe2ef077da17a22fbdb5fd23 |
IEDL.DBID | RPM |
ISSN | 0007-0920 |
IngestDate | Tue Sep 17 21:21:50 EDT 2024 Fri Sep 13 06:56:40 EDT 2024 Fri Aug 23 02:00:10 EDT 2024 Thu May 23 23:37:57 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
License | From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c478t-fb3bcd07e895379bfea58bcaba301479cbe89b5a6fe2ef077da17a22fbdb5fd23 |
Notes | Current Address: Georgia Pediatric Urology, Children’s Healthcare of Atlanta, Emory University, Atlanta, GA, USA. Current Address: Womack Army Medical Center, Fort Bragg, NC, USA. These authors contributed equally to this work and are joint first authors. Present Address: Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA, USA. |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680466/ |
PMID | 28972965 |
PQID | 1961409176 |
PQPubID | 41855 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5680466 proquest_journals_1961409176 crossref_primary_10_1038_bjc_2017_318 pubmed_primary_28972965 |
PublicationCentury | 2000 |
PublicationDate | 2017-11-07 |
PublicationDateYYYYMMDD | 2017-11-07 |
PublicationDate_xml | – month: 11 year: 2017 text: 2017-11-07 day: 07 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | British journal of cancer |
PublicationTitleAlternate | Br J Cancer |
PublicationYear | 2017 |
Publisher | Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group |
References | AR Jordan (BFbjc2017318_CR14) 2016; 8 AR Jordan (BFbjc2017318_CR15) 2015; 6 VB Lokeshwar (BFbjc2017318_CR29) 1997; 57 EA Turley (BFbjc2017318_CR46) 2016; 76 C Peng (BFbjc2017318_CR37) 2016; 138 F Takahashi-Yanaga (BFbjc2017318_CR45) 2013; 86 W Xu (BFbjc2017318_CR48) 2015; 9 VB Lokeshwar (BFbjc2017318_CR24) 2005; 65 T Saito (BFbjc2017318_CR42) 2013; 5 RL Ross (BFbjc2017318_CR41) 2016; 16 VB Lokeshwar (BFbjc2017318_CR31) 2002; 95 F Piccioni (BFbjc2017318_CR38) 2012; 22 TJ Yates (BFbjc2017318_CR49) 2013; 119 T Nakamura (BFbjc2017318_CR35) 1997; 43 LC Pagliaro (BFbjc2017318_CR36) 2003; 21 A Kultti (BFbjc2017318_CR22) 2009; 315 H Xu (BFbjc2017318_CR47) 2015; 8 JT Posey (BFbjc2017318_CR40) 2003; 63 VB Lokeshwar (BFbjc2017318_CR26) 2006; 66 E Camarri (BFbjc2017318_CR3) 1988; 79 R Singh (BFbjc2017318_CR44) 2016; 15 SH Hautmann (BFbjc2017318_CR12) 2001; 165 T Chanmee (BFbjc2017318_CR4) 2016; 375 I Kakizaki (BFbjc2017318_CR16) 2004; 279 S Ekici (BFbjc2017318_CR6) 2004; 112 H Nagase (BFbjc2017318_CR33) 2016; 46 CO McAtee (BFbjc2017318_CR32) 2014; 123 A Chi (BFbjc2017318_CR5) 2012; 118 CS Gomez (BFbjc2017318_CR10) 2009; 182 VB Lokeshwar (BFbjc2017318_CR27) 2010; 70 K Ikuta (BFbjc2017318_CR13) 2017; 140 VB Lokeshwar (BFbjc2017318_CR30) 2001; 276 BFbjc2017318_CR50 R Golshani (BFbjc2017318_CR8) 2007; 120 MW Kramer (BFbjc2017318_CR19) 2011; 117 J Leal (BFbjc2017318_CR23) 2016; 69 R Pinto-Leite (BFbjc2017318_CR39) 2014; 35 E Karousou (BFbjc2017318_CR18) 2016; 59 MW Kramer (BFbjc2017318_CR20) 2010; 57 E Arai (BFbjc2017318_CR2) 2011; 105 A Abate (BFbjc2017318_CR1) 2001; 27 VB Lokeshwar (BFbjc2017318_CR28) 2000; 163 I Kakizaki (BFbjc2017318_CR17) 2002; 269 M Nagata (BFbjc2017318_CR34) 2016; 2016 BJ Schmitz-Drager (BFbjc2017318_CR43) 2015; 94 R Golshani (BFbjc2017318_CR9) 2008; 68 S Guin (BFbjc2017318_CR11) 2016; 22 HF Kuipers (BFbjc2017318_CR21) 2016; 185 VB Lokeshwar (BFbjc2017318_CR25) 2005; 65 JJ Fantony (BFbjc2017318_CR7) 2015; 33 |
References_xml | – volume: 8 start-page: 3783 year: 2015 ident: BFbjc2017318_CR47 publication-title: Onco Targets Ther contributor: fullname: H Xu – volume: 315 start-page: 1914 year: 2009 ident: BFbjc2017318_CR22 publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2009.03.002 contributor: fullname: A Kultti – volume: 76 start-page: 2507 year: 2016 ident: BFbjc2017318_CR46 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-3114 contributor: fullname: EA Turley – volume: 276 start-page: 11922 year: 2001 ident: BFbjc2017318_CR30 publication-title: J Biol Chem doi: 10.1074/jbc.M008432200 contributor: fullname: VB Lokeshwar – volume: 43 start-page: 263 year: 1997 ident: BFbjc2017318_CR35 publication-title: Biochem Mol Biol Int contributor: fullname: T Nakamura – volume: 15 start-page: e187 year: 2016 ident: BFbjc2017318_CR44 publication-title: Clin Genitourin Cancer doi: 10.1016/j.clgc.2016.07.021 contributor: fullname: R Singh – volume: 59 start-page: 3 year: 2016 ident: BFbjc2017318_CR18 publication-title: Matrix Biol doi: 10.1016/j.matbio.2016.10.001 contributor: fullname: E Karousou – volume: 95 start-page: 61 year: 2002 ident: BFbjc2017318_CR31 publication-title: Cancer doi: 10.1002/cncr.10652 contributor: fullname: VB Lokeshwar – volume: 2016 start-page: 8205836 year: 2016 ident: BFbjc2017318_CR34 publication-title: Dis Markers doi: 10.1155/2016/8205836 contributor: fullname: M Nagata – volume: 63 start-page: 2638 year: 2003 ident: BFbjc2017318_CR40 publication-title: Cancer Res contributor: fullname: JT Posey – volume: 16 start-page: 553 year: 2016 ident: BFbjc2017318_CR41 publication-title: BMC Cancer doi: 10.1186/s12885-016-2570-0 contributor: fullname: RL Ross – volume: 68 start-page: 483 year: 2008 ident: BFbjc2017318_CR9 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-2140 contributor: fullname: R Golshani – volume: 35 start-page: 4599 year: 2014 ident: BFbjc2017318_CR39 publication-title: Tumour Biol doi: 10.1007/s13277-013-1604-3 contributor: fullname: R Pinto-Leite – volume: 5 start-page: 1068 year: 2013 ident: BFbjc2017318_CR42 publication-title: Oncol Lett doi: 10.3892/ol.2013.1124 contributor: fullname: T Saito – volume: 165 start-page: 2068 year: 2001 ident: BFbjc2017318_CR12 publication-title: J Urol doi: 10.1016/S0022-5347(05)66296-9 contributor: fullname: SH Hautmann – volume: 117 start-page: 1197 year: 2011 ident: BFbjc2017318_CR19 publication-title: Cancer doi: 10.1002/cncr.25565 contributor: fullname: MW Kramer – volume: 182 start-page: 1350 year: 2009 ident: BFbjc2017318_CR10 publication-title: J Urol doi: 10.1016/j.juro.2009.06.070 contributor: fullname: CS Gomez – volume: 8 start-page: 24262 year: 2016 ident: BFbjc2017318_CR14 publication-title: Oncotarget doi: 10.18632/oncotarget.10529 contributor: fullname: AR Jordan – volume: 6 start-page: 182 year: 2015 ident: BFbjc2017318_CR15 publication-title: Front Immunol doi: 10.3389/fimmu.2015.00182 contributor: fullname: AR Jordan – volume: 105 start-page: 1839 year: 2011 ident: BFbjc2017318_CR2 publication-title: Br J Cancer doi: 10.1038/bjc.2011.459 contributor: fullname: E Arai – volume: 185 start-page: 372 year: 2016 ident: BFbjc2017318_CR21 publication-title: Clin Exp Immunol doi: 10.1111/cei.12815 contributor: fullname: HF Kuipers – volume: 70 start-page: 2613 year: 2010 ident: BFbjc2017318_CR27 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-3185 contributor: fullname: VB Lokeshwar – volume: 22 start-page: 1274 year: 2016 ident: BFbjc2017318_CR11 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-1706 contributor: fullname: S Guin – volume: 22 start-page: 400 year: 2012 ident: BFbjc2017318_CR38 publication-title: Glycobiology doi: 10.1093/glycob/cwr158 contributor: fullname: F Piccioni – volume: 112 start-page: 121 year: 2004 ident: BFbjc2017318_CR6 publication-title: Int J Cancer doi: 10.1002/ijc.20368 contributor: fullname: S Ekici – volume: 21 start-page: 456 year: 2003 ident: BFbjc2017318_CR36 publication-title: Urol Oncol doi: 10.1016/S1078-1439(03)00032-2 contributor: fullname: LC Pagliaro – volume: 57 start-page: 773 year: 1997 ident: BFbjc2017318_CR29 publication-title: Cancer Res contributor: fullname: VB Lokeshwar – volume: 138 start-page: 2499 year: 2016 ident: BFbjc2017318_CR37 publication-title: Int J Cancer doi: 10.1002/ijc.29975 contributor: fullname: C Peng – volume: 119 start-page: 61 year: 2013 ident: BFbjc2017318_CR49 publication-title: Cancer doi: 10.1002/cncr.27661 contributor: fullname: TJ Yates – volume: 65 start-page: 2243 year: 2005 ident: BFbjc2017318_CR25 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-2805 contributor: fullname: VB Lokeshwar – volume: 9 start-page: 317 year: 2015 ident: BFbjc2017318_CR48 publication-title: Cell Adh Migr doi: 10.1080/19336918.2015.1016686 contributor: fullname: W Xu – volume: 69 start-page: 438 year: 2016 ident: BFbjc2017318_CR23 publication-title: Eur Urol doi: 10.1016/j.eururo.2015.10.024 contributor: fullname: J Leal – volume: 46 start-page: 190 year: 2016 ident: BFbjc2017318_CR33 publication-title: Pancreas doi: 10.1097/MPA.0000000000000741 contributor: fullname: H Nagase – volume: 140 start-page: 469 year: 2017 ident: BFbjc2017318_CR13 publication-title: Int J Cancer doi: 10.1002/ijc.30460 contributor: fullname: K Ikuta – volume: 269 start-page: 5066 year: 2002 ident: BFbjc2017318_CR17 publication-title: Eur J Biochem doi: 10.1046/j.1432-1033.2002.03217.x contributor: fullname: I Kakizaki – volume: 27 start-page: 223 year: 2001 ident: BFbjc2017318_CR1 publication-title: Drugs Exp Clin Res contributor: fullname: A Abate – volume: 163 start-page: 348 year: 2000 ident: BFbjc2017318_CR28 publication-title: J Urol doi: 10.1016/S0022-5347(05)68050-0 contributor: fullname: VB Lokeshwar – volume: 33 start-page: 387 e1 year: 2015 ident: BFbjc2017318_CR7 publication-title: Urol Oncol doi: 10.1016/j.urolonc.2015.04.014 contributor: fullname: JJ Fantony – volume: 375 start-page: 20 year: 2016 ident: BFbjc2017318_CR4 publication-title: Cancer Lett doi: 10.1016/j.canlet.2016.02.031 contributor: fullname: T Chanmee – volume: 79 start-page: 198 year: 1988 ident: BFbjc2017318_CR3 publication-title: Recent Prog Med contributor: fullname: E Camarri – volume: 279 start-page: 33281 year: 2004 ident: BFbjc2017318_CR16 publication-title: J Biol Chem doi: 10.1074/jbc.M405918200 contributor: fullname: I Kakizaki – volume: 123 start-page: 1 year: 2014 ident: BFbjc2017318_CR32 publication-title: Adv Cancer Res doi: 10.1016/B978-0-12-800092-2.00001-0 contributor: fullname: CO McAtee – volume: 86 start-page: 191 year: 2013 ident: BFbjc2017318_CR45 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2013.04.022 contributor: fullname: F Takahashi-Yanaga – volume: 120 start-page: 1712 year: 2007 ident: BFbjc2017318_CR8 publication-title: Int J Cancer doi: 10.1002/ijc.22222 contributor: fullname: R Golshani – volume: 57 start-page: 86 year: 2010 ident: BFbjc2017318_CR20 publication-title: Eur Urol doi: 10.1016/j.eururo.2009.03.057 contributor: fullname: MW Kramer – volume: 66 start-page: 11219 year: 2006 ident: BFbjc2017318_CR26 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-1121 contributor: fullname: VB Lokeshwar – volume: 118 start-page: 2394 year: 2012 ident: BFbjc2017318_CR5 publication-title: Cancer doi: 10.1002/cncr.26520 contributor: fullname: A Chi – volume: 65 start-page: 7782 year: 2005 ident: BFbjc2017318_CR24 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-1022 contributor: fullname: VB Lokeshwar – volume: 94 start-page: 1 year: 2015 ident: BFbjc2017318_CR43 publication-title: Urol Int doi: 10.1159/000369357 contributor: fullname: BJ Schmitz-Drager – ident: BFbjc2017318_CR50 doi: 10.1093/jnci/djv085 |
SSID | ssj0009087 |
Score | 2.4981253 |
Snippet | Molecular markers of clinical outcome may aid in designing targeted treatments for bladder cancer. However, only a few bladder cancer biomarkers have been... Background:Molecular markers of clinical outcome may aid in designing targeted treatments for bladder cancer. However, only a few bladder cancer biomarkers... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 1507 |
SubjectTerms | 1-Phosphatidylinositol 3-kinase AKT protein Animals Antineoplastic Agents - pharmacology Apoptosis Biomarkers Biomarkers, Tumor - metabolism Bladder cancer Cancer CD44 antigen Cell proliferation E-cadherin Epithelial-Mesenchymal Transition - drug effects Genomes Humans Hyaluronic acid Hyaluronic Acid - metabolism Hymecromone - pharmacology Kaplan-Meier Estimate Medical prognosis Mesenchyme Metastases Mice Mice, Nude Oral administration Prognosis Toxicity Translational Therapeutics Tumors Urinary bladder Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology Xenografts β-Catenin |
SummonAdditionalLinks | – databaseName: ProQuest Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5qBfEivq1W2YMeQ_PaR7yIiKUI9WTBW9gnVkpa2_Tgv3cnSatV8Bg2bMLMPubxzTcA19LoRDOtgzi23kFhRgaZSmkgmDaRdk7LBGuHh89sMEqfXulrCwarWhiEVa7OxOqgNlONMfKeXynIzRRx1pMKowC67N3NPgLsH4V51qaZxhZsR36JYhMH8fAN9shCUbNnYmAui8MGAh8moqfekckw4t57FZuX0x-L8zdw8sdN1N-HvcaEJPe1zg-gZYtD2Bk2SfIjkINPOVlWnLdE6rEhdRCDjAuiJnjQzIlGXc9vyWxaIlrIz4Y4rWKKpM0EK_IRtDNfEFkY8qNCi9S48cUxjPqPLw-DoOmkEOiUizJwKlHahNyKjCY8U85KKpSWSqJHxTOt_IiikjkbWxdybmTEZRw7ZRR1Jk5OoF1MC3sGRAsXCme4otamVGWZtzi8Dye9KeP8k-3AzUqE-awmzMirRHcici_qHEWde1F3oLuSb95sm0X-reQOnNaiXk_iPUPvCDDaAb6hhPULSJS9OVKM3yrCbMpEmDJ2_v8nL2AXf64qNORdaJfzpb30FkeprqrF9AW9PNpp priority: 102 providerName: ProQuest |
Title | Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28972965 https://www.proquest.com/docview/1961409176/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC5680466 |
Volume | 117 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NaxsxEB2SFEovoWmaxmlidGiOa--urJU2t9YkmIKNCQn4tuiTujhrYzuH_PvM7Idx0lsvC4u0QoxmpXnSmyeAH9pZbjNrozT1CFAyp6PcDESkMusSG4LVnHKHx5Ns9Dj4PROzAxBtLkxF2rdm3isXT71y_qfiVq6ebL_lifWn46HIFMK6rH8Ih5LzFqK3SruxqoUyaQ8uT-OG7R5z1Td_SbQwkQhU6Z4-xBoYWtKysr8k_RNnvqdL7q0_d5_huAkc2c-6gydw4Msv8HHcHI2fgh696MVzpXTLtJ07Vm9dsHnJzIKmlzWzNMLrG7ZabokjhK0RO6tcklQzozx8ouqsN0yXju3lZbGaLb75Co93tw_DUdTcnxDZgVTbKBhurIulV7ngMjfBa6GM1UYTjpK5NVhihM6CT32IpXQ6kTpNg3FGBJfyMzgql6U_B2ZViFVw0gjvB8LkOcYZiNw0BjAB33wHrlsTFqtaJqOojre5KtDqBVm9QKt34LK1b9H8LJsCJwGS3Upk1oFvtal3jbRj1AH5ZhB2FUge-20Jek0lk914ycV_f_kdPlG_q8xDeQlH2_Wzv8IQZGu66HgziU81TLrw4dftZHrfrdzwFd3N40A |
link.rule.ids | 230,315,733,786,790,891,12083,12250,21416,27957,27958,31754,33301,33779,43345,43614,43840,53827,53829,74102,74371,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3JTsMwEB2xSMAFsVNWH-AYkcbxEi4IIaqylBNIvUVeRVGVlrYc-Hs8SQotSBwjR040Y49nefMMcKasoYYbEyWJCwEKtyrKdMoiyY1tGu-Notg73Hni7Zf0vsu6dcJtXMMqpzaxNNR2YDBHfhFWCnIzNQW_Gr5HeGsUVlfrKzQWYTmlNEVIn-iKH9LdWFacmZiOy5K4Br7HVF7oN-QvbIoQs8r5I-mPn_kbLjlz_rQ2YL12HMl1pelNWHDFFqx06tL4Nqj2p-p_lEy3RJmeJVXqgvQKovtoXkbEoIZHl2Q4mCBGKMyG6KxigFTNBPvwEaozGhNVWDLTl0UqtPh4B15at8837ai-PyEyqZCTyGuqjY2FkxmjItPeKSa1UVphHCUyo8OIZop7lzgfC2FVU6gk8dpq5m1Cd2GpGBRuH4iRPpbeCs2cS5nOsuBnhMhNBQfGhyfXgPOpCPNhRZORl-VtKvMg6hxFnQdRN-BoKt-83izj_Ee1DdirRP09SYgHg_vPWQPEnBK-X0B67PmRovda0mQzLkPwzw_-_-QprLafO4_5493TwyGs4Y-WrYbiCJYmow93HHyOiT4pF9YX_ZjZ1A |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9tAEB4aB0wuoenTadLuoT0Ky5L2oV5C2sa4DxtTavBN7JO4GNmx5UP-fXek9auFHsWKlZiZ3Z2Z_eYbgPfS6FQzraMksT5AYUZGucpoJJg2Pe2clinWDg9HbDDJvk3pNOCf1gFWud0T643aLDTmyLveUpCbqcdZ1wVYxPhL_2b5EGEHKbxpDe00TuCUZ4x6Cz_9dDca_9xT8MaiYdDE5FyexAEGH6eiq34jm2GP-whWHB9Q_3idf4MnD06j_lM4D24kuW30fgFPbPkM2sNwUf4c5OBRzjc17y2RemZIk8ggs5KoOW42K6JR36uPZLmoEDHkZ0OsVrlA4maCVfkI3FmtiSwNOajSIg12fP0CJv27X58HUeimEOmMiypyKlXaxNyKnKY8V85KKpSWSmJUxXOt_IiikjmbWBdzbmSPyyRxyijqTJK-hFa5KO1rIFq4WDjDFbU2oyrPvdfh4zjp3Rnnn2wHPmxFWCwb0oyivuxOReFFXaCoCy_qDlxt5VuEpbMu9oruwKtG1LtJfHTogwFGO8CPlLB7Acmyj0fK2X1Nmk2ZiDPGLv__yXfQ9lZV_Pg6-v4GzvA_67pDfgWtarWx194BqdTbYFl_AKph33c |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hyaluronic+acid+family+in+bladder+cancer%3A+potential+prognostic+biomarkers+and+therapeutic+targets&rft.jtitle=British+journal+of+cancer&rft.au=Morera%2C+Daley+S&rft.au=Hennig%2C+Martin+S&rft.au=Talukder%2C+Asif&rft.au=Lokeshwar%2C+Soum+D&rft.date=2017-11-07&rft.pub=Nature+Publishing+Group&rft.issn=0007-0920&rft.eissn=1532-1827&rft.volume=117&rft.issue=10&rft.spage=1507&rft_id=info:doi/10.1038%2Fbjc.2017.318&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon |